Biotechnology equities’ extended run towards year-end was helped by positive news-flow in December
Value inflection in biotech: Karuna Therapeutics acquired for USD 14 billion, and Cytokinetics announces clinical trial success in heart dysfunction.
Karuna Therapeutics, an Arctic Aurora LifeScience and Arctic Aurora Biotech Select portfolio company, that on December 22 announced an agreement with Bristol-Myers Squibb to be acquired for USD 14 billion in equity value. The deal corresponded to an approximate 53% premium on the previous closing price of Karuna.
In September this year, Karuna submitted a drug approval application to the US Food and Drug Administration (FDA) for its leading drug candidate for treating schizophrenia. The application comes after two successful Phase 3 trials where Karuna was able show competitive drug profile versus standard-of-care schizophrenia drugs available today. The drug both had a compelling efficacy profile, and importantly, a benign side effect profile which otherwise is an obstacle for the drugs currently used for this disease. The medical need in schizophrenia is profound with an estimated 24 million patients worldwide and relatively little innovation in the field for the past decades.
On December 27, Cytokinetics announced positive Phase 3 results with their lead candidate drug aficamten in obstructive hypertrophic cardiomyopathy (HCM). Measured by patient’s oxygen uptake during exercise, aficamten offered a statistically significant improvement over placebo. But more importantly, the drug profile appears competitive compared to a drug already approved for this patient group. When comparing safety measures, the aficamten also appears to offer a more compelling profile.
HCM is a rare hereditary heart condition whereby the heart muscle walls are thickened, and blood flow becomes restricted. Aficamten work by inhibiting the activity of myosin, a motor protein that makes the heart muscle contract. By relaxing the heart muscle relative to its untreated state this drug class has now shown to increase blood flow through the heart. Like Karuna, Cytokinetics is also held by both Arctic Aurora LifeScience and Arctic Aurora Biotech Select. As a consequence of the positive trial results, Cytokinetics share prices rocketed up 83% on the day of the news release.
Latest news
Arctic Asset Management - Markedskommentar April 2024
Oslo Børs var sterkeste aksjemarked i Norden i april hjulpet av oppgang i råvarepriser, god fart i shipping og en svakere krone. Den nordiske Vinx-indeksen (i NOK) leverte også positiv avkastning. Amerikanske S&P 500 og verdensindeksen falt tilbake med motvind i økte amerikanske langrenter. Flere av de store amerikanske tech-selskapene leverte Q1-resultater bedre enn konsensus forventning og har dermed drevet mye av kursoppgangen mot slutten av måneden.
Arctic Asset Management - Obesity companies continue to deliver superior growth in the first quarter of 2024
Both Novo Nordisk and Eli Lilly have reported quarterly results in recent days and continue to show growth rates well above their peers in the pharmaceutical industry.
Arctic Asset Management - Arctic Midt i Måneden - Hvordan bruker proffene informasjonsflyten i rapporteringssesongen
I denne episoden av Arctic Midt i Måneden er aksjeforvalter Ole Dahl og analytiker Arild Huitfeldt på besøk i studio hos Albert Collett, der de gir innblikk i hvordan de jobber for å oppnå best mulig avkastning for investorene.
Arctic Asset Management - Biopharma is finally improving depression treatment outcomes and providing more options to patients
On Tuesday April 16, psychiatry specialists, and Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding, Intra-Cellular Therapies rallied nearly 25% on positive Phase 3 clinical trial depression results. The news adds to the list of good news in the treatment landscape for Major Depressive Disorder or MDD, colloquially known as depression.
Arctic Asset Management - Markedskommentar Mars 2024
Mars ble en bra børsmåned internasjonalt, og det var bredde i oppgangen med alle sektorer i S&P500 og nær alle sektorer på Oslo Børs og i Norden opp. En god måned også for kreditt, med stigning i DNBs Nordiske High Yield indeks og fall i kredittpåslagene både i USA og Europa. Sentralbankene signaliserte reduserte forventninger til fremtidige rentekutt, og ble mer tydelige på når første rentekutt kommer. Markedet priset som følge inn færre rentekutt enn tidligere.
Arctic Asset Management - Emerging gene therapies provide new option to children wilth Duchenne Muscular Dystrophy
Multiple companies develop gene therapies to improve the state of children suffering from Duchenne Muscular Dystrophy, a rare and debilitating genetic disease that leads to muscle degeneration and substantially reduced life expectancy.